Pemigatinib approved in the United States for the treatment of FGFR1 myeloid or lymphoid tumors (MLNs) 15/12/2022
The U.S. FDA approved the development of infigratinib, a targeted new drug for bile duct cancer, in China 15/12/2022
Intrahepatic bile duct cancer｜CUHK Research: The combination of SIRT-90 and chemotherapy can prolong the survival of patients with bile duct cancer 15/12/2022
Devimistat, a new anti-cholangiocarcinoma drug, has been recognized as an orphan drug for cholangiocarcinoma. 21/06/2022 Bile duct cancer
Precise treatment of IDH1 mutant bile duct cancer! Targeted drug Tibsovo approved by FDA for new indications 21/06/2022 Bile duct cancer IDHI gene
FDA approves Ivosidenib for advanced or metastatic bile duct cancer with IDH1 mutation 21/06/2022 Bile duct cancer IDHI gene
Can IVETINIB (TIBSOVO) improve the survival of disease progression in patients with bile duct cancer? 21/06/2022 Bile duct cancer IDHI gene
How long can bile duct cancer metastasis last? The survival rate of the targeted new drug Pemigatinib is unexpected 15/06/2022 Bile duct cancer FGFR gene
